An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued
Apr 16
Chinese (SSE) Healthcare Sector Analysis
UpdatedApr 19, 2024
DataAggregated Company Financials
Companies468
- 7D-1.8%
- 3M-7.0%
- 1Y-23.4%
- YTD-14.5%
Over the last 7 days, the Healthcare industry has dropped 1.6%, driven by a pullback from Jiangsu Hengrui Medicine of 5.8%. In contrast, Yunnan Baiyao GroupLtd has gained 10%. However, the industry is down 24% over the past year. Earnings are forecast to grow by 24% annually.
Sector Valuation and Performance
Has the Chinese Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 19 Apr 2024 | CN¥5.5t | CN¥2.3t | CN¥174.9b | 29.3x | 31.7x | 2.4x |
| Sun, 17 Mar 2024 | CN¥6.0t | CN¥2.3t | CN¥178.6b | 31.4x | 33.8x | 2.6x |
| Tue, 13 Feb 2024 | CN¥5.7t | CN¥2.3t | CN¥179.7b | 27.4x | 31.5x | 2.5x |
| Thu, 11 Jan 2024 | CN¥6.2t | CN¥2.3t | CN¥176.9b | 33.3x | 34.9x | 2.7x |
| Sat, 09 Dec 2023 | CN¥6.6t | CN¥2.3t | CN¥178.2b | 35.6x | 37x | 2.9x |
| Mon, 06 Nov 2023 | CN¥6.5t | CN¥2.3t | CN¥177.2b | 35.2x | 36.7x | 2.8x |
| Wed, 04 Oct 2023 | CN¥6.5t | CN¥2.3t | CN¥185.2b | 33x | 34.9x | 2.8x |
| Fri, 01 Sep 2023 | CN¥6.2t | CN¥2.3t | CN¥186.7b | 32.3x | 33.4x | 2.7x |
| Sun, 30 Jul 2023 | CN¥6.7t | CN¥2.3t | CN¥192.8b | 34.2x | 34.6x | 2.9x |
| Tue, 27 Jun 2023 | CN¥6.5t | CN¥2.3t | CN¥191.9b | 33.3x | 33.7x | 2.9x |
| Thu, 25 May 2023 | CN¥7.0t | CN¥2.3t | CN¥191.7b | 36.7x | 36.4x | 3.1x |
| Sat, 22 Apr 2023 | CN¥7.1t | CN¥2.3t | CN¥235.4b | 37.5x | 30x | 3.1x |
| Mon, 20 Mar 2023 | CN¥7.0t | CN¥2.2t | CN¥233.5b | 37.5x | 29.9x | 3.1x |
| Wed, 15 Feb 2023 | CN¥7.5t | CN¥2.2t | CN¥233.1b | 39.3x | 32.1x | 3.4x |
| Fri, 13 Jan 2023 | CN¥7.1t | CN¥2.2t | CN¥232.2b | 36.3x | 30.5x | 3.2x |
| Sun, 11 Dec 2022 | CN¥7.1t | CN¥2.2t | CN¥231.9b | 38.6x | 30.6x | 3.2x |
| Tue, 08 Nov 2022 | CN¥7.0t | CN¥2.2t | CN¥231.0b | 37.2x | 30.2x | 3.2x |
| Thu, 06 Oct 2022 | CN¥6.1t | CN¥2.1t | CN¥223.7b | 31.1x | 27.5x | 2.9x |
| Sat, 03 Sep 2022 | CN¥6.5t | CN¥2.1t | CN¥218.2b | 34.1x | 29.9x | 3.1x |
| Mon, 01 Aug 2022 | CN¥6.5t | CN¥2.1t | CN¥227.5b | 32.5x | 28.6x | 3.2x |
| Wed, 29 Jun 2022 | CN¥6.8t | CN¥2.0t | CN¥226.0b | 35.2x | 30.3x | 3.3x |
| Fri, 27 May 2022 | CN¥6.2t | CN¥2.0t | CN¥225.8b | 32x | 27.3x | 3x |
| Sun, 24 Apr 2022 | CN¥6.2t | CN¥2.0t | CN¥215.7b | 31.4x | 28.7x | 3.1x |
| Tue, 22 Mar 2022 | CN¥7.1t | CN¥2.0t | CN¥213.2b | 37.6x | 33.2x | 3.6x |
| Thu, 17 Feb 2022 | CN¥6.8t | CN¥1.9t | CN¥207.8b | 35.2x | 32.9x | 3.5x |
| Sat, 15 Jan 2022 | CN¥7.8t | CN¥1.9t | CN¥205.5b | 43x | 38.1x | 4.1x |
| Mon, 13 Dec 2021 | CN¥7.7t | CN¥1.9t | CN¥204.4b | 38.2x | 37.9x | 4x |
| Wed, 10 Nov 2021 | CN¥7.2t | CN¥1.9t | CN¥202.4b | 34.6x | 35.6x | 3.8x |
| Fri, 08 Oct 2021 | CN¥7.7t | CN¥1.9t | CN¥203.9b | 36x | 37.9x | 4.1x |
| Sun, 05 Sep 2021 | CN¥7.3t | CN¥1.9t | CN¥200.6b | 36.5x | 36.3x | 3.9x |
| Tue, 03 Aug 2021 | CN¥8.5t | CN¥1.9t | CN¥199.3b | 41.2x | 42.6x | 4.5x |
| Fri, 07 May 2021 | CN¥8.4t | CN¥1.8t | CN¥189.6b | 37.5x | 44.4x | 4.7x |
Price to Earnings Ratio
44.4x
Current Industry PE
- Investors are relatively neutral on the Chinese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 34.1x.
- The 3-year average PS ratio of 3.3x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 2.7% per year over the last three years.
- Meanwhile revenues for these companies have grown 8.4% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare sector?
| CN Market | -0.36% | |
| Healthcare | -1.76% | |
| Healthcare Services | 0.54% | |
| Pharma | -1.52% | |
| Medical Equipment | -1.75% | |
| Biotech | -2.65% | |
| Life Sciences | -4.39% | |
| Healthtech | -8.40% | |
Industry PE
- Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 328x.
- Analysts are expecting annual earnings growth of 62.7%, which is higher than its past year's earnings decline of 23.8% per year.
- Investors are most pessimistic about the Life Sciences industry, which is trading below its 3-year average of 42.4x.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 63% over the next 5 years.
- This is better than its past earnings decline of 24% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 20% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 538 Yunnan Baiyao GroupLtd | CN¥56.00 | 10.5% +CN¥9.5b | 1.7% | PE24.4x | |
| 600161 Beijing Tiantan Biological Products | CN¥28.16 | 9.1% +CN¥3.9b | 4.8% | PE39.8x | |
| 600436 Zhangzhou Pientzehuang Pharmaceutical | CN¥226.42 | 2.9% +CN¥3.8b | -16.1% | PE49.1x | |
| 963 Huadong Medicine | CN¥31.52 | 7.0% +CN¥3.6b | -25.0% | PE19.4x | |
| 999 China Resources Sanjiu Medical & Pharmaceutical | CN¥57.81 | 5.2% +CN¥2.8b | 4.5% | PE20x |